DE69733694D1 - Verwendung von proteinen aus der mk familie als hämatopoietischer faktor - Google Patents

Verwendung von proteinen aus der mk familie als hämatopoietischer faktor

Info

Publication number
DE69733694D1
DE69733694D1 DE69733694T DE69733694T DE69733694D1 DE 69733694 D1 DE69733694 D1 DE 69733694D1 DE 69733694 T DE69733694 T DE 69733694T DE 69733694 T DE69733694 T DE 69733694T DE 69733694 D1 DE69733694 D1 DE 69733694D1
Authority
DE
Germany
Prior art keywords
family
hematopoietic
csf
proteins
hematopoietic factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69733694T
Other languages
English (en)
Other versions
DE69733694T2 (de
Inventor
Makoto Kikuchi
Shinya Ikematsu
Munehiro Oda
Sadatoshi Sakuma
Takashi Muramatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MURAMATSU, TAKASHI, NAGOYA, AICHI, JP
Original Assignee
Meiji Dairies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp
Publication of DE69733694D1 publication Critical patent/DE69733694D1/de
Application granted granted Critical
Publication of DE69733694T2 publication Critical patent/DE69733694T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69733694T 1996-07-10 1997-07-10 Verwendung von proteinen aus der mk familie als hämatopoietischer faktor Expired - Fee Related DE69733694T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP19853196 1996-07-10
JP19853196 1996-07-10
PCT/JP1997/002401 WO1998001151A1 (fr) 1996-07-10 1997-07-10 Nouvelle utilisation de la famille mk comme facteur hematopoietique

Publications (2)

Publication Number Publication Date
DE69733694D1 true DE69733694D1 (de) 2005-08-11
DE69733694T2 DE69733694T2 (de) 2006-07-06

Family

ID=16392704

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733694T Expired - Fee Related DE69733694T2 (de) 1996-07-10 1997-07-10 Verwendung von proteinen aus der mk familie als hämatopoietischer faktor

Country Status (6)

Country Link
US (2) US6383480B1 (de)
EP (1) EP0937461B1 (de)
AT (1) ATE299030T1 (de)
CA (1) CA2260014A1 (de)
DE (1) DE69733694T2 (de)
WO (1) WO1998001151A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
AU756279B2 (en) * 1997-07-14 2003-01-09 Medical Therapies Limited Agents comprising Midkine or its inhibitor as active ingredient
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1147777A1 (de) * 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Kombination von Defibrotid und G-CSF und ihre Verwendung zur Aktivierung der hämatopoiestischen Vorläuferzellen
US20040042997A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of regenerating human tissue
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040076605A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of regenerating human tissue
US20040043009A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of repairing primate mammalian tissue
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040076620A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of repairing primate mammalian tissue
FR2853663B1 (fr) * 2003-04-14 2007-08-31 Aventis Pharma Sa Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
JP4651282B2 (ja) 2004-01-21 2011-03-16 田辺三菱製薬株式会社 造血幹細胞及び造血前駆細胞の増幅方法
WO2006005360A1 (en) * 2004-07-12 2006-01-19 Sorin Group Italia S.R.L. Devices and methods for growing human cells
CA2579764A1 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
JP4791770B2 (ja) * 2004-12-06 2011-10-12 株式会社セルシグナルズ 心筋障害又は心不全の治療もしくは予防組成物
US20070131375A1 (en) * 2005-12-09 2007-06-14 Husky Injection Molding Systems Ltd. Thixo-molding shot located downstream of blockage
WO2010036373A2 (en) * 2008-09-26 2010-04-01 Duke University Hematopoietic stem cell growth factor
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
KR20190112197A (ko) 2012-06-22 2019-10-02 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
JP2016507066A (ja) 2013-02-08 2016-03-07 インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法
EP3026122A1 (de) 2014-11-27 2016-06-01 Gentium S.p.A. Zellenbasiertes Verfahren zur Bestimmung der Wirksamkeit von Defibrotid
US11698369B2 (en) 2016-01-12 2023-07-11 Oncotracker, Inc. Methods for monitoring immune status of a subject
EP3639028A4 (de) 2017-06-13 2021-04-14 Inc. Onco Tracker Diagnostische, prognostische und überwachungsverfahren für maligne solide tumoren

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307402B1 (de) * 1986-05-06 1993-08-11 Genetics Institute, Inc. Herstellung von m-csf
US4868119A (en) 1986-12-11 1989-09-19 Genetics Institute, Inc. Hematopoietic growth factors
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
FR2666477A1 (fr) 1990-08-31 1992-03-06 Sodern Tube neutronique a flux eleve.
WO1992006712A1 (en) 1990-10-12 1992-04-30 Amgen Inc. Megakaryocyte maturation factors
US5409825A (en) * 1991-04-09 1995-04-25 Indiana University Foundation Expansion of human hematopoietic progenitor cells in a liquid medium
EP0535336A3 (en) * 1991-09-30 1993-05-19 American Cyanamid Company Mk protein as cell growth inhibitor
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
DE4240635C2 (de) * 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
EP0722330A4 (de) * 1993-10-07 1997-09-10 Systemix Inc Methoden zur analyse von humanen stammzellen

Also Published As

Publication number Publication date
US20020132984A1 (en) 2002-09-19
EP0937461A1 (de) 1999-08-25
EP0937461B1 (de) 2005-07-06
WO1998001151A1 (fr) 1998-01-15
EP0937461A4 (de) 2002-10-16
CA2260014A1 (en) 1998-01-15
US6939669B2 (en) 2005-09-06
ATE299030T1 (de) 2005-07-15
US6383480B1 (en) 2002-05-07
AU3459397A (en) 1998-02-02
AU733451B2 (en) 2001-05-17
DE69733694T2 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
DE69733694D1 (de) Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
CA2150016A1 (en) Pyrrolopyrimidines as CRF Antagonists
DE69434213D1 (de) Verwendung von Zusatzstoffen in Treibstoffzusammensetzungen
DE69432409D1 (de) Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
FI842829A (fi) Cykliska ureakondensat, behandlingskompositioner foer textilier och papper och nya cykliska ureafoereningar.
DE69917296D1 (de) Neue substituierte triazolverbindungen
DE3853663D1 (de) Plättchenförmiges Zinkoxid-Pulver und Zusammensetzung für äusserliche Verwendung.
DE60236016D1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
RU94044324A (ru) СПОСОБ ПОЛУЧЕНИЯ ЗАМЕЩЕННЫХ СЛОЖНЫХ ЭФИРОВ ИЗОСЕРИНА С ИСПОЛЬЗОВАНИЕМ МЕТАЛАЛКОГОЛЯТОВ И β -ЛАКТАМОВ
MY115960A (en) Method of administering crf antagonists
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
ES2180654T3 (es) Poliisocianatos que contienen uretidiona y alofanato.
CA2418125A1 (en) Beta-lactams useful in the preparation of substituted isoserine esters
IT8448944A0 (it) Composizione contenente manganese e rame,combustibile che la contiene e relativo metodo per ridurre l'accensione di particelle di scarico
DE68907763D1 (de) Verwendung von schmieroelzusammensetzungen fuer kuehlapparate.
AR248151A1 (es) Composicion aislante tixotropica, metodo de transporte para la misma.
SI1086096T1 (en) Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
HK1033096A1 (en) Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculationdisorders
DE69006878D1 (de) Teilchenförmiger Reinigungsmittel-Zusatz, dessen Herstellung und Verwendung in Reinigungsmittelzusammensetzungen.
DE69014717D1 (de) Stabilisierte Zusammensetzungen von Metalloxidpulver.
ATE30008T1 (de) Stabilisierte zusammensetzung zur verwendung in pyrolytischer beschichtung von glas.
AU8402491A (en) Beta chain of the human gm-csf receptor and uses thereof
CA2104576A1 (en) A method for the treatment of tumours and sarcomas
ES2062024T3 (es) Nuevo pentapeptido y un procedimiento para su preparacion.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MURAMATSU, TAKASHI, NAGOYA, AICHI, JP

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee